North China Pharmaceutical Co., Ltd. (600812.SH) announced its wholly-owned subsidiary, Huasheng Company, recently obtained the Certification of Suitability to European Pharmacopoeia (CEP) for Polymyxin B Sulfate active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
Polymyxin B Sulfate treats acute infections caused by Pseudomonas aeruginosa-susceptible strains, serving as the primary medication for urinary tract, meningeal, and bloodstream infections induced by this pathogen. This therapeutic agent is also indicated for severe infections stemming from susceptible strains of Haemophilus influenzae (particularly meningeal infections), Escherichia coli (especially urinary tract infections), Enterobacter aerogenes (notably bacteremia), and Klebsiella pneumoniae (specifically bacteremia) when lower-toxicity alternatives prove ineffective or contraindicated.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。